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Abstract
Background
In response to DNA double-strand breaks, the histone protein H2AX becomes phosphory-
lated at its C-terminal serine 139 residue, referred to as γ-H2AX. Formation of γ-H2AX foci
is associated with recruitment of p53-binding protein 1 (53BP1), a regulator of the cellular
response to DNA double-strand breaks. γ-H2AX expression in peripheral blood mononu-
clear cells (PBMCs) was recently proposed as a diagnostic and disease activity marker for
multiple sclerosis (MS).
Objective
To evaluate the significance of γ-H2AX and 53BP1 foci in PBMCs as diagnostic and dis-
ease activity markers in patients with clinically isolated syndrome (CIS) and early relapsing-
remitting MS (RRMS) using automated γ-H2AX and 53BP1 foci detection.
Methods
Immunocytochemistry was performed on freshly isolated PBMCs of patients with CIS/early
RRMS (n = 25) and healthy controls (n = 27) with γ-H2AX and 53BP1 specific antibodies.
Nuclear γ-H2AX and 53BP1 foci were determined using a fully automated reading system,
assessing the numbers of γ-H2AX and 53BP1 foci per total number of cells and the
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percentage of cells with foci. Patients underwent contrast enhanced 3 Tesla magnetic reso-
nance imaging (MRI) and clinical examination including expanded disability status scale
(EDSS) score. γ-H2AX and 53BP1 were also compared in previously frozen PBMCs of
each 10 CIS/early RRMS patients with and without contrast enhancing lesions (CEL) and
10 healthy controls.
Results
The median (range) number of γ-H2AX (0.04 [0–0.5]) and 53BP1 (0.005 [0–0.2]) foci per
cell in freshly isolated PBMCs across all study participants was low and similar to previously
reported values of healthy individuals. For both, γ-H2AX and 53BP1, the cellular focus num-
ber as well as the percentage of positive cells did not differ between patients with CIS/
RRMS and healthy controls. γ-H2AX and 53BP1 levels neither correlated with number nor
volume of T2-weighted lesions on MRI, nor with the EDSS. Although γ-H2AX, but not
53BP1, levels were higher in previously frozen PBMCs of patients with than without CEL, γ-
H2AX values of both groups overlapped and γ-H2AX did not correlate with the number or
volume of CEL.
Conclusion
γ-H2AX and 53BP1 foci do not seem to be promising diagnostic or disease activity biomark-
ers in patients with early MS. Lymphocytic DNA double-strand breaks are unlikely to play a
major role in the pathophysiology of MS.
Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative dis-
ease of the central nervous system and the leading cause for permanent neurological disability
in young adults [1]. The diagnosis of MS can be challenging, in particular in the early phase of
the disease [2]http://www.ncbi.nlm.nih.gov/pubmed/18805839. Furthermore, only a propor-
tion of MS lesions seen on conventional magnetic resonance imaging (MRI) is associated with
overt clinical symptoms, complicating clinical assessment of disease activity [3,4]. Finally, the
course of MS is highly variable as is the response to immunomodulatory therapies [5]. Thus,
there is an immanent need for reliable diagnostic, disease activity, prognostic, and therapy
response markers in patients with MS [6]. Numerous blood-based biomarkers have therefore
been evaluated in MS, though very few have entered clinical practice [7]
In response to DNA double-strand breaks the histone protein H2AX becomes phosphory-
lated at its serine 139 residue in the vicinity of the DNA break site [8]. The thus phosphorylated
H2AX is termed γ-H2AX and plays a central role in the cellular DNA double-strand break
response pathway by providing a platform for the recruitment of other DNA damage response
and repair factors [9,10]. Among those, one key element is p53-binding protein 1 (53BP1),
which, much like γ-H2AX, accumulates in discrete nuclear foci at DNA double-strand break
sites and has important regulatory functions for the cellular response to DNA double-strand
breaks [11,12]. Nuclear γ-H2AX and 53BP1 foci can be visualized in isolated peripheral blood
mononuclear cells (PBMCs) by immunofluorescence microscopy. Indeed, digital fluorescence
microscopy employing novel pattern recognition algorithms has recently been established for
Gamma-H2AX and 53BP1 in Early Multiple Sclerosis
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the automated analysis of DNA damage response foci, paving the way for a much needed stan-
dardization in this field [13–16].
A recent pilot study suggested γ-H2AX expression in PBMCs as a possible diagnostic as
well as disease activity marker for relapsing remitting MS (RRMS), as patients with RRMS
exhibited higher levels of γ-H2AX positive cells than healthy controls and levels of γ-H2AX
positive cells were associated with MRI measures of disease activity in patients with RRMS
[17]. Oxidative stress has been implicated in the pathogenesis of MS [18,19]. Because elevated
levels of reactive oxygen species may cause DNA damage, a possible link between DNA damage
markers in PBMCs and MS may be hypothesized [17].
To further scrutinize the possible association of lymphocytic DNA double-strand break
markers and MS, we herein analyzed nuclear γ-H2AX and 53BP1 foci in freshly isolated
PBMCs from 25 patients with clinically isolated syndrome (CIS) or early RRMS and 27 healthy
controls as well as in previously frozen PBMCs from 20 Patients with CIS or early RRMS and
10 healthy controls using fully automated immunofluorescence microscopy [14,15]. Moreover,
we correlated γ-H2AX and 53BP1 levels with MRI measures of disease activity.
Patients and Methods
Patients and healthy controls
The study was approved by the institutional review board of Charité–Universitätsmedizin Ber-
lin (EA1/182/10). All participants provided written informed consent.
PBMCs were freshly isolated from blood samples obtained by peripheral venipuncture from
25 patients with CIS or early RRMS and 27 age and sex matched healthy controls between
March and July 2014. Additionally, previously frozen PBMC samples, obtained between April
2012 and July 2014, from each 10 age and sex matched patients with CIS/early RRMS with and
without contrast enhancing lesions (CEL) and 10 age and sex matched healthy controls were
included in the study. All patients were participating in an ongoing prospective observational
study of patients with early MS (Berlin CIS Cohort; NCT01371071), which started recruitment
in January 2011. Inclusion criteria were: age>18 years, a first clinical event suggestive of
inflammatory demyelination (i.e. CIS) not meeting the McDonald 2010 criteria for RRMS [20]
within six months before inclusion into the study or a diagnosis of RRMS according to the
McDonald 2010 criteria within 24 months before inclusion into the study. Exclusion criteria
were: a history of alcohol or drug abuse, any conditions precluding MRI examinations and any
ocular diseases precluding optical coherence tomography. The patients investigated in the pres-
ent analysis had not been treated with corticosteroids for at least two months prior to inclusion
into the study. At the time of blood withdrawal, patients underwent a thorough neurological
examination, including determination of the expanded disability status scale (EDSS) score.
PBMC isolation
PBMCs were isolated from heparinized blood (27 ml) within 4.5 hours of blood withdrawal
through Biocoll (Biochrom GmbH, Berlin, Germany) density centrifugation at 760 g for 20
minutes at room temperature. The lymphocyte/monocyte fraction was recovered and washed
in phosphate buffered saline (PBS, Biochrom GmbH, Berlin, Germany) at 560 g for 20 minutes
and at 400 g for 15 minutes. Cell pellets were resuspended in PBS at a concentration of 1x106
cells/ml. Experiments shown in Figs 1 and 2 were performed with freshly isolated PBMCs.
Experiments shown in Fig 3 were performed with previously frozen PBMCs. Freezing and
thawing of PBMCs were carried out according to established protocols. PBMCs were frozen in
RPMI-1640 (Gibco, Thermo Fisher Scientific Inc., Waltham. USA) containing 10% dimethyl
sulfoxide (Sigma Aldrich Chemie GmbH, Munich, Germany), 20% fetal bovine serum
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(Biochrom GmbH, Berlin, Germany) and 1% Hepes (Gibco) and stored in liquid nitrogen. For
thawing, aliquots were removed from liquid nitrogen and thawed at 37°C for 1 minute. Cells
were quickly transferred into 10 ml of wash medium (5% fetal bovine serum, 1% Hepes and
94% RPMI-1640) at room temperature and washed two times at 300 g for 5 minutes before
resuspension in PBS at a concentration of 1x106 cells/ml.
Microscope Slide preparation
PBMCs were transferred to 6 well Teflon coated microscope slides (Tekdon Inc., Myakka City,
United States) at a concentration of 5x104 cells per well and incubated for 10 minutes at room
temperature. Cells were subsequently fixed with 2% paraformaldehyde (Merck Chemicals
GmbH, Schwalbach, Germany) for 15 minutes at room temperature. Slides were washed in
PBS for 30 minutes and stored in dry conditions at 4°C until further processing.
Immunocytochemistry
Immunocytochemistry was performed following standard operating procedures at Medipan
GmbH, Berlin-Dahlewitz, Germany. Fixed cells on the microscope slide were permeabilized
with Triton X 100 (0.2% in 1% bovine serum albumin [BSA]/PBS) (BioUltra, Sigma-Aldrich
Chemie GmbH, Taufkirchen, Germany) for five minutes at 4°C and subsequently washed
three times in 1% BSA/PBS at room temperature. For co-immunostaining, slides were simulta-
neously incubated with a mouse monoclonal IgG antibody specifically detecting H2AX phos-
phorylated at serine 139 (Merck Millipore, Billerica, USA) and with anti-53BP1 rabbit
Fig 1. Examples of γ-H2AX and 53BP1 foci in PBMCs. (A) Multiple nuclear γ-H2AX foci (green) are clearly
discernible in a lymphocyte of a healthy control. (B) Single 53BP1 focus (red) in a lymphocyte nucleus of a
patient with RRMS. (C) Colocalization of nuclear γ-H2AX and 53BP1 foci in a lymphocyte of a healthy control.
In the automated focus detection, the blue circle represents the DAPI stained nucleus. Small green and red
circles highlight γ-H2AX and 53BP1 foci as automatically detected by the AKLIDES1 reading system. The
system assigns distinct image (I) and object (O) numbers and indicates the number of foci detected in each
fluorescence channel (FITC or APC). Note the difference in highlighted (n = 7) and counted (n = 6) γ-H2AX
foci in (A), which is explained by a weaker focus fluorescence intensity not meeting the preset definitions for
scoring of γ-H2AX foci.
doi:10.1371/journal.pone.0147968.g001
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polyclonal IgG (Novus Biologicals, Cambridge, United Kingdom) at a dilution of 1:200 in 1%
BSA/PBS for one hour. After three further wash steps in PBS for ten minutes, secondary anti-
bodies, Alexa Fluor 488 goat anti-mouse IgG (detected in the FITC channel; Invitrogen
GmbH, Karlsruhe, Germany) and Alexa Fluor 647 goat anti-rabbit IgG H&L (detected in the
APC channel; Invitrogen GmbH, Karlsruhe, Germany), were added simultaneously in a dilu-
tion of 1:500 in 1% BSA/PBS for one hour at room temperature. Slides were washed again
three times in PBS for ten minutes and mounted using a 4,6´-diamidino-2-phenylindole
(DAPI) containing mounting medium (GA Generic Assays GmbH, Berlin-Dahlewitz, Ger-
many) for DNA counterstaining.
Automated analysis of γ-H2AX and 53BP1 foci
Enumeration of γ-H2AX and 53BP1 foci was carried out as previously described using the
automated AKLIDES1 reading system (Medipan GmbH, Berlin-Dahlewitz, Germany) [14–
16]. The system uses a motorized inverse fluorescence microscope (Olympus IX81, Olympus,
Hamburg, Germany) with a motorized scanning stage and is controlled by software using a set
of mathematical algorithms to detect and evaluate immunofluorescence patterns. For each
sample approximately 100 cells on each well were selected randomly for analysis. According to
Fig 2. γ-H2AX and 53BP1 levels in freshly isolated PBMCs of patients and healthy controls. (A) γ-H2AX foci per cell in patients with CIS/early RRMS
and healthy controls. (B) Percentage of γ-H2AX positive cells in patients with CIS/early RRMS and healthy controls. (C) 53BP1 foci per cell in patients with
CIS/early RRMS and healthy controls. (D) Percentage of 53BP1 positive cells in patients with CIS/early RRMS and healthy controls. Each data point
represents the median of n = 6 separate measurements per individual. In each of the six separate measurements approximately n = 100 cells were scored.
The horizontal bar indicates the median.
doi:10.1371/journal.pone.0147968.g002
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our presets, only convex nuclei with diameters between 2–15 μm were evaluated. This way,
monocytes, granulocytes, heavily damaged cells, and cell aggregates were excluded. As outlined
before, both cells with a high amount of induced DNA double-strand breaks as well as early
apoptotic cells can show a pan-nuclear staining [21–23]. However, γ-H2AX foci analysis by the
automated interpretation system AKLIDES1 cannot distinguish between these two instances.
Thus, to avoid confounding of apoptotic cells and cells with a high amount of induced DNA
double-strand breaks, cells with an γ-H2AX signal comprising70% of the DAPI signal were
excluded from the analysis [23]. The following exposure times were used for the different chan-
nels: DAPI default exposure 24 ms, FITC default exposure 1000 ms, APC default exposure
1000 ms. Sub-nuclear foci had to meet the following requirements to be counted as such: mini-
mum diameter 0.2 μm, maximum diameter 1.2 μm, minimum intensity 70 gray values on a 8
bit gray scale (0–255 with 0 being black) above background intensity. Results were expressed as
the quotient of the γ-H2AX or 53BP1 focus number divided by the total number of assessed
cells (cellular focus number) and as the percentage of cells carrying foci among all assessed
cells (percentage of positive cells). The median values from separate measurements of six sepa-
rate wells containing PBMCs from one individual were used for further statistical analysis. In
setup experiments, PBMC samples were split and either processed immediately or after 2.5 and
4.5 hours. Compared to immediately processed cells, no significant time dependent change of
Fig 3. γ-H2AX and 53BP1 in frozen PBMCs of CIS/early RRMS patients with and without CEL and healthy controls. (A) γ-H2AX foci per cell in patients
with CIS/early RRMSwithout CEL (CEL-; n = 10), with CEL (CEL+; n = 10) and healthy controls (HC; n = 10). (B) Percentage of γ-H2AX positive cells in
patients with CIS/early RRMSwithout CEL, with CEL and healthy controls. (C) 53BP1 foci per cell in patients with CIS/early RRMS without CEL, with CEL
and healthy controls. (D) Percentage of 53BP1 positive cells in patients with CIS/early RRMS without CEL, with CEL and healthy controls. The horizontal bar
indicates the median. *p<0.05, MannWhitney test.
doi:10.1371/journal.pone.0147968.g003
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γ-H2AX and 53BP1 foci could be observed 2.5 and 4.5 hours after blood withdrawal, arguing
against a possible confounding influence of time between blood withdrawal and PBMCs pro-
cessing on γ-H2AX and 53BP1 expression (data not shown).
Magnetic resonance imaging
Three-dimensional whole brainMR data (1mm3) were acquired on a 3 Tesla (3T) whole-body
MRI (Magnetom Trio with TIM, Siemens Healthcare AG, Erlangen, Germany), using a clinical
routine 12-channel head coil. For T2-weighted imaging (T2w), a single slab three-dimensional
T2w turbo-spin-echo (TSE) sequence with high sampling efficiency (SPACE) was selected (TE
388 ms, TR 6000 ms, flip angle 120°) as well as a three-dimensional fluid attenuated inversion
recovery sequence (SPACE-FLAIR; TE 502 ms, TR 5000 ms, TI 2100 ms, flip angle 120°), fol-
lowed by an axial two-dimensional double-echo proton density/T2w sequence (TE 14/87 ms, TR
3400 ms, flip angle 120°, voxel resolution 1 x 1 x 3 mm3, no gap). Contrast enhanced images were
acquired by a volumetric interpolated brain examination sequence optimized for short acquisition
time with asymmetric k-space sampling and interpolation (VIBE; 1mm3, TE 2.2 ms, TR 4.85 ms,
flip 9°) 8 min after weight adjusted 0.1 mMGadubutrol (Bayer Vital GmbH, Leverkusen, Ger-
many) injection. T2w lesions as well as CEL were counted. T2w as well as CEL lesion volume was
calculated using the OsiriX software toolbox (OsiriX foundation, Geneva, Switzerland) and in-
house applications. ExperiencedMRI raters were blinded to the results of any laboratory studies.
Statistics
Significance of different frequencies was assessed by 2 × 2 or 2 × 3 Fisher´s exact test. Signifi-
cance of differences in γ-H2AX and 53BP1 cellular focus numbers and percentage of positive
cells was assessed by MannWhitney test. Three-group comparisons were performed by Krus-
kall-Wallis test. Correlation analysis between DNA damage parameters, clinical data, and MRI
parameters was carried out by Spearman correlation. All statistical tests were performed with
GraphPad Prism Version 5.0d. P-values<0.05 were considered significant.
Results
Participants
Demographics, clinical and MRI data, as well as immunomodulatory treatments of the 25
patients with CIS (n = 12) or RRMS (n = 13) and the 27 healthy controls of which freshly iso-
lated PBMC were analyzed in this study are summarized in Table 1. The sex (p = 0.36) and age
distribution (p = 0.93) did not differ between the groups of patients and healthy controls.
Levels of γH2AX and 53BP1 in freshly isolated PBMCs do not differ in
patients with CIS/early RRMS and healthy controls
To compare the numbers of lymphocytic γ-H2AX and 53BP1 foci in freshly isolated PBMCs
from patients with CIS/early RRMS and healthy controls, we used a previously established
immunocytochemical staining technique combined with an automated reading system [14,15].
With this methodology, γ-H2AX and 53BP1 foci could be visualized as clearly discernible
intranuclear dots, examples of which, as well as of the automated detection of γ-H2AX and
53BP1 foci, are shown in Fig 1.
Intranuclear γ-H2AX foci were detectable in PBMCs of 23 out of 25 (92%) patients with
CIS/early RRMS and 26 out of 27 (96%) healthy controls (p = 0.6). While 53BP1 foci were over-
all less frequently detectable than γ-H2AX foci, the detection frequency of 53BP1 foci did nei-
ther differ between patients (14 out of 25; 56%) and controls (13 out of 27; 48%; p = 0.6). The
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PLOS ONE | DOI:10.1371/journal.pone.0147968 January 28, 2016 7 / 14
median (range) number of γ-H2AX foci per cell across all study subjects was low (0.04 [0–
0.49]), as was the median frequency of 53BP1 foci per cell across all study subjects (0.005 [0–
0.21]). The median (range) percentage of positive cells across all study subjects for γ-H2AX
was 4.02% (0–44.57) and for 53BP1 0.46% (0–15.79). Taken all study subjects together, there
was a strong correlation of γ-H2AX and 53BP1 foci numbers per cell (r = 0.60; p<0.0001) as
well as of the percentage of γ-H2AX and 53BP1 positive cells (r = 0.62; p<0.0001).
The number of γ-H2AX foci per cell did not differ (p = 0.49) between patients with CIS/
early RRMS and healthy controls (Fig 2A). Likewise, the percentage of cells positive for γ-
H2AX did not differ between patients and healthy controls (p = 0.49) (Fig 2B). Similarly, there
was no significant difference of 53BP1 focus numbers (p = 0.18) and of the percentage of
53BP1 positive cells between patients and healthy controls (p = 0.17) (Fig 2C and 2D). Further-
more, γ-H2AX focus numbers (p = 0.11) and the percentage of γ-H2AX positive cells
(p = 0.12) were not different in patients with CIS compared to patients with early RRMS. A
comparison of patients treated with immunomodulatory therapies (n = 10) and untreated
patients (n = 15) revealed no significant difference of γ-H2AX focus numbers per cell or the
percentage of γ-H2AX positive cells (p = 0.11 for both) and no significant difference for 53BP1
focus numbers per cell or the percentage of positive cells (p = 0.17 for both). Likewise, a sub-
group analysis of smokers (n = 7) and non-smokers (n = 18) within the group of patients
showed no significant difference of γ-H2AX focus numbers per cell (p = 0.62) or of the percent-
age of γ-H2AX positive cells (p = 0.54) and no significant difference of 53BP1 focus numbers
per cell (p = 0.88) or of the percentage of 53BP1 positive cells (p = 0.92). Finally, neither in the
groups of patients nor of healthy controls was there a correlation of age and γ-H2AX or 53BP1
focus numbers per cell or of the percentage of γ-H2AX or 53BP1 positive cells.
Levels of γ-H2AX and 53BP1 in freshly isolated PBMCs do not appear to
be promising disease activity markers in patients with CIS/early RRMS
We next asked whether levels of γ-H2AX and 53BP1 in freshly isolated PBMCs from patients
with CIS/early RRMS might be associated with radiological or clinical measures of MS. We
Table 1. Demographic and clinical data of patients and healthy controls of which freshly isolated
PBMCswere analyzed in this study.
Patients Healthy Controls P-value
Number 25 27 n/a
CIS/early RRMS (number) 12/13 n/a n/a
Female/Male (number) 16/9 21/6 p = 0.36
Age, years, median (range) 33 (21–52) 29 (20–56) p = 0.93
EDSS, median (range) 1.5 (0–5.5) n/a n/a
T2w-lesions, number, median (range) 5 (0–107) n/a n/a
CEL, number, median (range) 0 (0–1) n/a n/a
Immunomodulatory treatment, number
None 15 n/a n/a
Glatiramer acetate 5 n/a n/a
Interferon-beta 3 n/a n/a
Dimethyl fumarate 1 n/a n/a
Fingolimod 1 n/a n/a
CIS = clinically isolated syndrome, RRMS = relapsing remitting multiple sclerosis, EDSS = expanded
disability status scale, T2w = T2 weighted, CEL = contrast enhancing lesions, n/a = not applicable
doi:10.1371/journal.pone.0147968.t001
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therefore correlated the number and volume of T2w lesions as well as the number and volume
of CEL on MRI performed at the time of blood withdrawal with levels of γ-H2AX and 53BP1.
In the vast majority of patients (23/25) MRI was performed on the day of blood withdrawal.
The delay between blood withdrawal and MRI in the remaining 2 patients was 5 and 6 days. γ-
H2AX focus numbers per cell and the percentage of γ-H2AX positive cells did not correlate
with T2w lesion load (r = 0.15; p = 0.49 and r = 0.13; p = 0.54) or T2w lesion volume (r = 0.14;
p = 0.45 and r = 0.13; p = 0.50). Likewise, 53BP1 focus numbers per cell and the percentage of
53BP1 positive cells did not correlate with T2w lesion load (r = 0.30; p = 0.13 and r = 0.33;
p = 0.13) and T2w lesion volume (r = 0.33; p = 0.08 and r = 0.38; p = 0.05). Only two patients
had each one CEL. Although one of these patients had relatively high γ-H2AX (0.46 foci/cell;
41.9% positive cells) and 53BP1 levels (0.20 foci/cell; 15.8% positive cells), the other patient
had low γ-H2AX (0.04 foci/cell; 3% positive cells) and 53BP1 levels (0.005 foci/cell, 0.5% posi-
tive cells). Clinical disability as measured by the EDSS did not correlate with γ-H2AX focus
numbers per cell (r = 0.20, p = 0.32) or percentage of γ-H2AX positive cells (r = 0.20, p = 0.33).
Likewise, there was no correlation of the EDSS and 53BP1 focus numbers per cell (r = 0.31;
p = 0.12) or the percentage of 53BP1 positive cells (r = 0.30; p = 0.14).
As seen in Fig 2A, there were three individuals among the patient group with relatively high
γ-H2AX foci numbers per cell. A detailed analysis of these three outliers showed no major
common characteristics. One of these patients (age: 33 years, sex: female, EDSS: 1.5) showed a
high T2w lesion count (n = 107), one CEL and was treated with fingolimod. One patient (age:
44 years, sex: male, EDSS: 5.5) had a moderate T2w lesion load (n = 13), no CEL, and was
treated with glatiramer acetate. The third patient (age: 35, sex: male, EDSS: 0) had one T2w
lesion without corresponding contrast enhancement and did not receive any immunomodula-
tory therapy.
Analysis of γ-H2AX and 53BP1 in frozen PBMCs from patients with CIS/
early RRMS with and without CEL and healthy controls
Because of the small number of freshly isolated PBMC samples from patients with CIS/early
RRMS with CEL, we aimed to increase the number of patients with CEL. As for logistic reasons
we were unable to obtain fresh PBMCs from a higher number of patients with CEL, we used
previously frozen PBMCs for this part of our study. Thus, we additionally determined gamma-
H2AX or 53BP1 foci in frozen PBMCs of 10 patients with CIS/early RRMS with CEL, 10
patients with CIS/early RRMS without CEL and 10 healthy controls. Demographics, clinical
and MRI findings of these patients and controls are summarized in Table 2.
In the majority of patients (18/20) MRI was performed on the day of blood withdrawal. The
delay between blood withdrawal and MRI in the remaining 2 patients was 5 and 14 days.
Patients with CEL had higher numbers of γ-H2AX foci per cell than patients without CEL
(p = 0.03) and patients with CEL had a higher percentage of γ-H2AX positive cells (p = 0.03)
than patients without CEL (Fig 3A and 3B). However, the γ-H2AX focus number per cell
(p = 0.2) and the percentage of γ-H2AX positive cells (p = 0.63) did not differ between patients
with CEL and healthy controls. Furthermore, a three-group comparison of patients with CEL,
patients without CEL and healthy controls by Kruskal-Wallis test demonstrated no significant
differences between the three groups in the number of γ-H2AX foci per cell (p = 0.09) as well
as the percentage of γ-H2AX positive cells (p = 0.06). Neither the number of γ-H2AX foci per
cell (r = 0.31; p = 0.39) nor the percentage of γ-H2AX positive cells (r = 0.15; p = 0.68) corre-
lated with the number of CEL. Similarly, neither the number of γ-H2AX foci per cell (r = 0.16;
p = 0.66) nor the percentage of γ-H2AX positive cells (r = 0.16; p = 0.66) correlated with the
volume of CEL.
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Neither the number of 53BP1 foci per cell (p = 0.91) nor the percentage of 53BP1 positive
cells (p = 0.63) differed between patients with and without CEL (Fig 3C and 3D). Likewise,
Kruskal-Wallis tests showed no significant differences of the number of 53BP1 foci per cell
(p = 0.52) as well as the percentage of 53BP1 positive cells (p = 0.49) between patients with
CEL, patients without CEL and healthy controls.
Discussion
In this study, we analyzed the significance of γ-H2AX and 53BP1 foci in nuclei of PBMCs as
potential diagnostic and disease activity markers for CIS/early RRMS using immunocytochem-
istry combined with fully automated immunofluorescence microscopy. The key findings of this
work are an absence of any significant differences of γ-H2AX and 53BP1 foci levels between
patients and healthy controls and no correlation of γ-H2AX and 53BP1 levels with MRI mea-
sures of MS and the EDSS in patients with CIS/early RRMS.
The median levels of γ-H2AX observed in our study, expressed as number of foci per cell
(0.04), were similar to previously reported levels of γ-H2AX foci per cell in healthy subjects
(0.05–0.1 foci/cell, see Valdiglesias et al. for review) [24,25]. Our data therefore confirm that
there is a low background rate of DNA damage foci in isolated human PBMCs. Low levels of
lymphocytic DNA damage foci and underlying DNA double-strand breaks may thus represent
a physiological phenomenon, which likely has no harmful consequences as it is counteracted
by DNA damage repair mechanisms [26]. As expected, lymphocytic γ-H2AX and 53BP1 foci
were strongly correlated, consistent with the concept that generation of γ-H2AX foci in
response to DNA double-strand breaks provides a platform for the recruitment of further
DNA damage response proteins [10]. However, γ-H2AX and 53BP1 foci did not always coloca-
lize (see Fig 1B), suggesting that γ-H2AX might not be a necessary prerequisite for recruitment
of 53BP1 or that expression of 53BP1 exceeds the duration of γ-H2AX expression.
The absence of any significant differences of γ-H2AX or 53BP1 foci between patients with
CIS/early RRMS and healthy controls suggests that lymphocytic DNA double-strand breaks
are not associated with CIS/early MS and, therefore, appear unlikely to play a major role in the
pathophysiology of MS. Our data are in contrast to previous findings by Grecchi et al., who
Table 2. Demographic and clinical data of patients and healthy controls of which previously frozen PBMCswere analyzed in this study.
Patients without CEL Patients with CEL Healthy Controls P-value
Number 10 10 10 n/a
CIS/early RRMS (number) 4/6 1/9 n/a p = 0.30
Female/Male (number) 5/5 6/4 6/4 p = 0.81
Age, years, median (range) 32.3 (24–51) 29 (22–51) 28.5 (20–49) p = 0.97
EDSS, median (range) 1.5 (0–5.5) 1.75 (0–3.5) n/a p = 0.67
T2w-lesions, number, median (range) 12 (2–32) 16 (7–79) n/a p = 0.12
CEL, number, median (range) 0 2 (1–3) n/a n/a
CEL, volume in cm3, median (range) n/a 0 (0.02–0.38) n/a n/a
Immunomodulatory treatment, number
None 3 7 n/a p = 0.18
Glatiramer acetate 4 0 n/a
Interferon-beta 2 3 n/a
Dimethyl fumarate 1 0 n/a
CIS = clinically isolated syndrome, RRMS = relapsing remitting multiple sclerosis, EDSS = expanded disability status scale, T2w = T2 weighted,
CEL = contrast enhancing lesions, n/a = not applicable
doi:10.1371/journal.pone.0147968.t002
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reported a significantly (p = 0.025) higher percentage of γ-H2AX positive cells, as measured by
immunofluorescence microscopy and manual evaluation of 500 cells per individual, in 19
patients with RRMS compared to 13 healthy controls, though there was a considerable overlap
between both groups [17]. Among the reasons for the disparate findings may be the larger sam-
ple size of the current study as well as different patient characteristics with more patients in the
earliest phase of MS in our work. Nevertheless, the similar EDSS values of the patients included
in the two studies do not suggest major differences in clinical disability between the two patient
populations. Although the study by Grecchi et al. included treatment naive patients only, the
fact that some patients in our study were treated with immunomodulatory therapies does like-
wise not seem to be a confounder, as we did not observe any differences of γ-H2AX and 53BP1
in treated vs. untreated patients. The study by Grecchi et al. and our study used different meth-
ods for the fixation of cells. However, as in each study the method of fixation was identical for
patients and controls, it appears unlikely that different fixation methods may explain the differ-
ent results of both studies. While in contrast to the study by Grecchi et al. few of our patients
did not undergo blood withdrawal and MRI on the same day, we do not feel that the short
delay between blood withdrawal and MRI in these few patients might have distorted our
results. It should be noted that the percentages of γ-H2AX positive cells reported by Grecchi
et al. are higher than previously reported in PBMCs of healthy controls [25,27,28] and that the
immunocytochemical staining of γ-H2AX positive cells shown in the work of Grecchi et al.
suggests that cells with a pan-nuclear γ-H2AX staining, possibly representing apoptotic cells,
were included in the analysis. Altogether, using a highly standardized and previously evaluated
method for enumeration of discrete nuclear γ-H2AX foci, we could not observe an association
of γ-H2AX foci with CIS/early RRMS, suggesting that γ-H2AX foci in PBMCs do not seem to
be a promising diagnostic biomarker for CIS/early RRMS. Our results are consistent with the
notion that MS patients have no generally increased risk of DNA-damage related diseases such
as malignancies and, consequently, are unlikely to express elevated levels of DNA-damage
related markers [29].
We found no correlation of γ-H2AX or 53BP1 foci with the number or volume of T2w
lesions on cranial MRI, indicating that γ-H2AX or 53BP1 foci are not associated with these
classical MRI markers of MS disease burden. Evaluation of γ-H2AX or 53BP1 foci in freshly
isolated PBMCs with respect to CEL was limited by the fact that only two patients had CEL.
Nevertheless, the very different γ-H2AX and 53BP1 foci levels in these two patients do not
seem to suggest an association of γ-H2AX and 53BP1 foci with CEL.
To further address a possible association γ-H2AX and 53BP1 levels with CEL, we performed
an additional analysis using previously frozen PBMCs of 10 patients with CIS/early RRMS with
CEL, 10 patients with CIS/early RRMS without CEL and 10 healthy controls. Although, remi-
niscent of findings by Grecchi et al. [17], the number of γ-H2AX foci per cells as well as the
percentage of γ-H2AX positive cells were higher in patients with as compared to patients with-
out CEL, these data should be interpreted with great caution. Firstly, a two group comparison
of γ-H2AX levels between patients with CEL and healthy controls and a three group compari-
son of γ-H2AX levels between patients with CEL, patients without CEL and healthy controls
revealed no significant differences. Secondly, correction for multiple testing, e.g. by the Bonfer-
roni method, would abolish the statistical significance of the differences between patients with
and without CEL. Thirdly, there was no correlation between γ-H2AX levels and the number or
volume of CEL. Fourthly, both the number of γ-H2AX foci per cell and the percentage of γ-
H2AX positive cells completely overlapped between the three groups, questioning the clinical
applicability and meaningfulness of γ-H2AX levels as a marker of disease activity. Altogether,
although γ-H2AX levels appeared to be higher in two-group comparisons of patients with as
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compared to patients without CEL, our findings do not seem to suggest that γ-H2AX levels
may be a promising disease activity marker for CIS/early RRMS.
Strengths of our study are the use of a standardized automated scoring method, minimizing
observer influence and allowing for large numbers of scored cells per individual. Indeed, our
automated reading system may also be useful to analyze other potential biomarkers in PBMCs
of patients with MS with distinct subcellular staining patterns. Among the limitations of this
work is the sample size. In particular, the small number of freshly isolated PBMCs from indi-
viduals with CEL precluded definitive conclusions on the association of γ-H2AX and 53BP1
levels in freshly isolated PBMCs with CEL.
In conclusion, the present study suggests that nuclear γ-H2AX and 53BP1 foci in PBMCs
do not distinguish patients with CIS/early RRMS from healthy controls, arguing against a role
of these parameters as diagnostic biomarkers for CIS/early MS. Furthermore, γ-H2AX and
53BP1 foci do not seem to be promising disease activity biomarkers in patients with CIS/early
RRMS. Lymphocytic DNA double-strand breaks are thus unlikely to play a major role in the
pathophysiology of MS.
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